MGNX
Macrogenics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
Market Cap: 1.33 Billion
Primary Exchange: NASDAQ
Website: https://www.macrogenics.com/
Shares Outstanding: 62 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.4927305183902098
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2881 trading days
From: 2014-01-17 To: 2024-03-07
Lowest Point:
MacroGenics: Margetuximab's Potential Makes It Massively Undervalued
via: SeekingAlpha at 2019-06-10 09:45:00:000
Notice: All factual information herein has been obtained from the companys latest SEC filings, except otherwise stated. MacroGenics, Inc. ( MGNX ) is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics to modulate the human immune response … read more...
MacroGenics: Margetuximab's Potential Makes It Massively Undervalued
via: SeekingAlpha at 2019-06-10 09:45:00:000
Notice: All factual information herein has been obtained from the companys latest SEC filings, except otherwise stated. MacroGenics, Inc. ( MGNX ) is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics to modulate the human immune response … read more...
MacroGenics: Margetuximab's Potential Makes It Massively Undervalued
via: SeekingAlpha at 2019-06-10 09:45:00:000
Notice: All factual information herein has been obtained from the companys latest SEC filings, except otherwise stated. MacroGenics, Inc. ( MGNX ) is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics to modulate the human immune response … read more...
MacroGenics: Margetuximab's Potential Makes It Massively Undervalued
via: SeekingAlpha at 2019-06-10 09:45:00:000
Notice: All factual information herein has been obtained from the companys latest SEC filings, except otherwise stated. MacroGenics, Inc. ( MGNX ) is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics to modulate the human immune response … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|